PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2017.47320185041462-1466Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell TherapyYongxian Hu, Jiasheng Wang, Chengfei Pu, Kui Zhao, Qu Cui, Guoqing Wei, Wenjun Wu, Lei Xiao, Yang Xiao, Jinping Wang, Zhao Wu, He Huanghttp://e-crt.org/upload/pdf/crt-2017-473.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2017.473, http://e-crt.org/upload/pdf/crt-2017-473.pdf
Bone Marrow Transplantation10.1038/s41409-018-0412-12018Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapyAiyun Jin, Jingjing Feng, Zhudan Wang, Li Jiang, Yongxian Hu, Kui Zhao, He Huanghttp://www.nature.com/articles/s41409-018-0412-1.pdf, http://www.nature.com/articles/s41409-018-0412-1, http://www.nature.com/articles/s41409-018-0412-1.pdf
Molecular Therapy10.1016/s1525-0016(16)34988-7201321S249653. Chimeric Antigen Receptor T-Cell Therapy for Companion Canines with Spontaneous B-Cell Non-Hodgkin Lymphomahttps://api.elsevier.com/content/article/PII:S1525001616349887?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525001616349887?httpAccept=text/plain
Molecular Therapy10.1016/s1525-0016(16)34349-0201321S5-S614. Administration of GD2 Chimeric Antigen Receptor Modified, Tri-Virus Specific Cytotoxic T Lymphocytes after HLA Mismatched Allogeneic Stem Cell Transplantation for Relapsed, Refractory Neuroblastomahttps://api.elsevier.com/content/article/PII:S1525001616343490?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525001616343490?httpAccept=text/plain
Molecular Therapy10.1016/s1525-0016(16)35781-1201422S296-S297768. Improved Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Refractory and Relapsed Leukemiahttps://api.elsevier.com/content/article/PII:S1525001616357811?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525001616357811?httpAccept=text/plain
Molecular Therapy10.1016/s1525-0016(16)35778-1201422S295765. Treatment of Chemotherapy-Refractory B-Cell Malignancies with Anti-CD19 Chimeric Antigen Receptor T Cellshttps://api.elsevier.com/content/article/PII:S1525001616357781?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525001616357781?httpAccept=text/plain
Molecular Therapy10.1016/s1525-0016(16)34986-3201321S248-S249651. Tumor Targeting Using CD19-Specific CAR (Chimeric Antigen Receptor) for B-Cell Lymphomahttps://api.elsevier.com/content/article/PII:S1525001616349863?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525001616349863?httpAccept=text/plain
Cancer Gene Therapy10.1038/s41417-018-0073-72019Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphomaFang Bao, Wei Wan, Ting He, Feifei Qi, Guanghua Liu, Kai Hu, Xin-an Lu, Ping Yang, Fei Dong, Jing Wang, Hongmei Jinghttp://www.nature.com/articles/s41417-018-0073-7.pdf, http://www.nature.com/articles/s41417-018-0073-7, http://www.nature.com/articles/s41417-018-0073-7.pdf
Advances in Cell and Gene Therapy10.1002/acg2.44201921e44Corrigendum: Dawn of chimeric antigen receptor T cell therapy in non-Hodgkin LymphomaKarlo Perica, M. Lia Palomba, Renier J. Brentjenshttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Facg2.44, http://onlinelibrary.wiley.com/wol1/doi/10.1002/acg2.44/fullpdf
OncoTargets and Therapy10.2147/ott.s81472010167Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma Youneshttps://www.dovepress.com/getfile.php?fileID=7610